BIO Asia – Taiwan 2021 conference and exhibition to be held from July 21 to 25
With the theme of this year’s conference “A New Era for Biotechnology”, the event expects to explore breakthrough opportunities in the post-pandemic era.
The Taiwan Bio Industry Organization (Taiwan BIO) and the Global Biotechnology Innovation Organization (BIO) jointly announced that BIO Asia – Taiwan 2021 will be held as scheduled from July 21 to 25.
Pre-opening access begins July 19, giving attendees more time to learn about participating businesses and to set up matchmaking meetings. With the theme of this year’s conference “A New Era for Biotechnology”, the industry confidently awaits further breakthroughs and opportunities as the world emerges from the grip of the pandemic.
Topics for the conference include pandemic control, advanced therapies, precision medicine, digital health, and investment and collaboration. An exceptional lineup of international speakers have been confirmed, including 2020 Nobel Laureate Michael Houghton, renowned inventor and entrepreneur Robert Langer from MIT, and many more.
This year, BIO Asia – Taiwan will once again feature forums and exhibitions, BIO’s One-on-one ™ partnership platform available 24 hours a day during the conference, and a comprehensive program of company presentations. Nearly 100 local and foreign companies, including from Europe, the United States, the Philippines and Australia, will participate in the company presentation program. The exhibition will present more than 550 companies and institutes. BIO Asia – Taiwan 2021 will once again offer many opportunities for business meetings, networking and collaboration, more important than ever as the post-pandemic era approaches.
As BIO Asia-Taiwan enters its third year, for the benefit of the international public, preview sessions will be held for the first time to increase online engagement opportunities with participating companies and exhibitors, and to help plan meetings through the BIO One-on-one Partnering ™ platform. This platform will be accessible 24 hours a day for easy use across time zones and regions.
Greater participation and organization than ever of international industry leaders
Johnsee Lee, Chairman of the BIO Asia-Taiwan 2021 Organizing Committee, reflected on the critical role the biomedical industry is playing during the COVID-19 pandemic. “Countries around the world have turned to their biotechnology industries to provide testing, diagnostics, vaccines, prevention and control products, all to fight the pandemic. Taiwan’s biotechnology sector also contributed. At the same time, Taiwan must do more, continue to reach out to the global biotechnology community and seek partners to carve out a place for itself in the international value chain, ”said Lee.
In order to broaden international participation, the conference also convened an international committee, with members including Joseph Damond, executive vice president of international affairs at BIO; Yoshiaki Tsukamoto, Executive Director, Japan Bioindustry Association (JBA); Albert Yu, President of Hong Kong BIO (HKBIO); Christopher Ko, President of Korea BIO; Damian O’Connell, CEO of Experimental Drug Research and Development (A * STAR), Singapore; Sirasak Teparkum, Deputy Director General, Thailand Center of Excellence for Life Sciences (TCELS); Murali PM, Chairman, Jananom Private Limited, India; David Flores, President of BioCentury; and Andrew Wylegala, CEO, American Chamber of Commerce in Taiwan (AmCham). The members of the International Committee have all confirmed their participation and the promotion of BIO Asia-Taiwan through their respective networks.
This year, the participation of international pharmaceutical companies is more important than ever; Amgen, AstraZeneca, Bristol-Myers Squibb (BMS), Chugai, Cytiva, Eli Lilly, GlaxoSmithKline (GSK), Johnson and Johnson, Merck (MSD), Novartis, Pfizer, Sanofi, Takeda and Roche will all participate as exhibitors or speakers at BIO Asia – Taiwan 2021.
Stellar lineup of international speakers to herald “A Courageous New Era for Biotechnology”
Notable international speakers this year include former Taiwan Vice President Chen Chien-jen who will share his vision for the future of precision medicine. Also in attendance will be Robert Langer from MIT; known as Edison of Medicine, inventor and entrepreneur, founder of vaccine company Moderna and over 40 other biotech companies. Langer’s presentation will focus on technological commercialization and innovation. Additionally, 2020 Nobel Laureate Michael Houghton will share his knowledge of virus discovery and treatment. And Graham Lewis, vice president of IQVIA, the world’s largest provider of medical information; and Claire Love from PwC will share their perspective on the biomedical market and investment considerations.
Under the theme Fighting the Pandemic, Chunhuei Chi, director of the Center for Global Health at Oregon State University, will take a deep dive into preventing global pandemics; Asher Yeshaihu Salmon, Head of the Department of International Relations at the Israeli Ministry of Health, to present Israel’s successes in pandemic prevention and vaccine delivery; and Dr. Li Bingying from National Taiwan University to summarize the current state of pandemic control and prevention in Taiwan.
In finance and investment, executives include Hongbo Lu, venture capital partner of Vivo Capital; Sinclair Dunlop, founder of life science venture capital firm Epidarex Capital; Darren Carroll of the Polaris Partners; partner; Michael Brinkman, Managing Director of Investment Bank Jefferies & Company; and Rick Tsai, partner of Axil Capital.
Leading names in advanced therapies to be showcased at BIO Asia – Taiwan 2021
BIO Asia – Taiwan 2021 will feature world-renowned speakers in the field of cytokines, including 2020 Tang Prize winner Professor Marc Feldmann of the University of Oxford; Charles Dinarello, professor at the University of Colorado; and Professor Tadamitsu Kishimoto of Osaka University. Didier Dargent, head of international markets for cell and gene therapy at Novartis Oncology; and Jennifer Mao, VP, Clinical Operations, Greater China, IQVIA will explore the area of gene therapy. The event will share new information on the state of Taiwan’s contract cell therapy development and manufacturing (CDMO) companies.
In digital health and related fields, including biomedical AI and big data, speakers include Mark Effinggam, Deputy Managing Director, UK Biobank; Ann Aerts, director of the Novartis Foundation; Olivier Delannoy, global digital manager at AstraZeneca – Cardiovascular renal and metabolic diseases; Xinying Su, director of translational medicine at Pfizer China; Laura Chu, Genentech; as well as many other opinion leaders and experts.
International Zone, Biosimilar Drug Zone at the exhibition
At the exhibition, the United States, United Kingdom and Canada are among the countries that will expand their presence in the “international zone”. This year, a special “Biosimilar Drugs Zone” will feature leading domestic and foreign biosimilar manufacturers including Taikang, Amgen, Celltrion, Fresenius Kabi, Sandoz and Viatris. In addition, Belgium, Switzerland, Germany, Poland, Austria, Malaysia, the Philippines and others have confirmed their participation in this year’s Conference.
Johnsee Lee, chairman of the organizing committee, invites the world to see Taiwan’s achievements and ambitions in pandemic prevention and control, and the opportunities in the industry in the post-pandemic era. The event also aspires to an opportunity for Taiwan to enter overseas markets.
Registration for the event is currently open. The pre-registration discount will end on June 18.
Event website: https://bioasiataiwan.com